Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05470920 · ClinicalTrials.gov registry record · NA
Genetic Testing Decision Aid
A NA study of Pancreas Adenocarcinoma and Epithelial Ovarian Carcinoma, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 350
- Enrollment target
- 2
- Study locations
NCT05470920: Recruiting NA study of Pancreas Adenocarcinoma and Epithelial Ovarian Carcinoma, sponsored by Massachusetts General Hospital.
NCT05470920 is a NA study of Pancreas Adenocarcinoma and Epithelial Ovarian Carcinoma that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 350 participants, above the 44-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (695% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05470920, a NA study of Pancreas Adenocarcinoma and Epithelial Ovarian Carcinoma, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancreatic cancer
Primary Outcome
Average change in score on a 10-question knowledge survey to assess basic information about genetics and genetic testing that was covered in their appointment. Scores on the scale range from 0-10. Higher values in the change in knowledge survey score suggest greater amount of knowledge gained in the genetics session.
Conditions Studied
Interventions
- BEHAVIORAL Electronic Decision Aid
- BEHAVIORAL Pre-Test Genetic Counseling
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Mass General at North Shore Cancer Center - Danvers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2022-10-14 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT05470920 shows while recruiting
NCT05470920 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 44-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (695% higher).
The record links to 2 conditions, with Pancreas Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Electronic Decision Aid is the first listed.
NCT05470920 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05470920 about?
NCT05470920 is a clinical study titled "Genetic Testing Decision Aid". This is a randomized trial to evaluate the effectiveness of an electronic decision aid tool versus a traditional genetic counselor session for multi-gene panel testing for people with ovarian or pancreatic cancer
What is the current status of trial NCT05470920?
This trial is currently recruiting. It is a NA study. The enrollment target is 350 participants. The study started on 2022-10-14. Estimated completion is 2026-12-31.
What conditions does trial NCT05470920 study?
This clinical trial studies the following conditions: Pancreas Adenocarcinoma, Epithelial Ovarian Carcinoma.
What interventions are being tested in trial NCT05470920?
The interventions under investigation include: Electronic Decision Aid (BEHAVIORAL), Pre-Test Genetic Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT05470920?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05470920 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05470920's enrollment target sits among peer trials
350 1st of 10 higher than 10 of 10 other Pancreas Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
RECRUITING · Phase 2
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
RECRUITING · Phase 2
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI